Science At BMS

Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below:

[Science At BMS @ScienceAtBMS]

Our precision-focused approach to cancer research combines molecular and clinical expertise with insights from causal human biology to help guide scientific discovery. Learn more about our approach to cancer research: https://t.co/yvG62D907J

#ESMO26 #OneBMS

[Science At BMS @ScienceAtBMS]

MTAP deletion is a genomic alteration found across multiple tumor types. Explore the biology and evolving unmet need in this patient population: https://t.co/HMOOEBsvl2

#ESMO26

[Science At BMS @ScienceAtBMS]

Today at #ESMO26, we presented late-breaking results from a Phase 3 study in patients with EGFR-mutant #NSCLC. View the presentation: https://t.co/3tNFrUQuQH

Learn more about the role of bispecific antibody-drug conjugates: https://t.co/FccLwYqAjz

[Science At BMS @ScienceAtBMS]

Join us tomorrow at #ESMO26 as Dr. Byoung Chul Cho presents efficacy and safety results from LBA76 Phase 2 ROSETTA Lung-107 trial.

Explore our research: https://t.co/PaA8rG1qo7

#NSCLC #LungCancer #BioNTech_Group

[Science At BMS @ScienceAtBMS]

Join us at #ESMO26 as we explore emerging therapeutic strategies in prostate and bladder cancer—from androgen receptor (AR)-directed innovations and radiopharmaceuticals to novel antibody-drug conjugate (ADC) approaches helping shape the future of care.

[Science At BMS @ScienceAtBMS]

Tomorrow at #ESMO26, Dr. @sara_lonardi1 will present the final overall survival results from the Phase 3 CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer (#CRC).

Explore our research: https://t.co/cegsU242Tw

[Science At BMS @ScienceAtBMS]

Join us tomorrow at #ESMO26 for a rapid oral presentation analyzing brain metastases subgroups from two Phase 2 studies in small-cell lung cancer (#SCLC) and triple-negative breast cancer (#TNBC).

Explore our research: https://t.co/J7UprdBIKJ

#BioNTech_Group

[Science At BMS @ScienceAtBMS]

On October 23 at #ESMO26, we’ll present late-breaking results from a randomized Phase 3 study in patients with previously treated or unresectable locally advanced or metastatic HR+/HER2- breast cancer.

Explore our research: https://t.co/RRECjsLSNm

[Science At BMS @ScienceAtBMS]

Lung cancer care is evolving fast. Join us at #ESMO26 as we explore how to advance the non-small cell lung cancer (#NSCLC) treatment landscape — from today’s standards of care to tomorrow’s emerging modalities—to shape what comes next for patients.

[Science At BMS @ScienceAtBMS]

Join us at #ECNP2026 as Dr. Leslie Citrome, Dr. Robert Perneczky and Dr. Silvana Galderisi explore the role of the cholinergic system in schizophrenia, bipolar disorder, and Alzheimer’s disease and discuss the therapeutic potential of muscarinic modulation in psychiatry.

[Science At BMS @ScienceAtBMS]

Join Dr. Yatham and Dr. Vieta at #ISBD2026 as they discuss the current treatment landscape, unmet needs, hypothesized disease mechanisms, emerging therapies and advances toward personalized management.

[Science At BMS @ScienceAtBMS]

During #IMS26, Dr. Doris Hansen will present results from a Phase 1 study focused on an investigational dual-targeting CAR T cell therapy approach being evaluated in patients with relapsed/refractory multiple myeloma.

See our latest research updates: https://t.co/Fj9lxmx29W

[Science At BMS @ScienceAtBMS]

Our diverse portfolio is designed to bridge critical gaps in myeloma care with innovative options for a broad range of patients. At #IMS26, we’re sharing the latest breakthroughs shaping the future of care.

[Science At BMS @ScienceAtBMS]

Join us at #IMS26 on Friday, September 25, for an oral presentation exploring the Phase 3 EXCALIBER-RRMM results.

Explore our latest hematology research updates: https://t.co/UysjNQqpZl

[Science At BMS @ScienceAtBMS]

We’re excited to be at this year’s #IMS26, showcasing the advances we’re making across protein degradation and cell therapy platforms to strengthen our approach for multiple myeloma treatment at every step of the journey.

[Science At BMS @ScienceAtBMS]

Today at #IMS26, we're sharing Phase 3 research evaluating hematologic adverse events and infections associated with treatment, as well as health-related quality of life, in relapsed/refractory multiple myeloma.

See more on our hematology research: https://t.co/LKHxiN7OZB

[Science At BMS @ScienceAtBMS]

OUT NOW: A special 2-part episode of #DoctoRxUnscripted! Dr. Tania Small, Chris Boerner, @ariannahuff and Dr. @Neil_Iyengar explore how precision oncology & behavioral science unite to transform patient outcomes. Watch: https://t.co/cK88c3DyEm

[Science At BMS @ScienceAtBMS]

At #IMS26 we’ll be presenting our latest updates in multiple myeloma, including advances from our protein degradation platform and research spanning our multiple myeloma portfolio and pipeline, including CAR T cell therapy.

Explore our research: https://t.co/cFPClFHBMS

[Science At BMS @ScienceAtBMS]

Join us at #ENGAGE26 as Susan Scanland, a geriatric nurse practitioner, explores the unmet needs and evidence-based management of psychosis and agitation in Alzheimer’s disease. Gain practical strategies for symptom assessment, care partner engagement and shared decision-making.

[Science At BMS @ScienceAtBMS]

Join us at #PsychCongress2026 for two Medical Innovation Theater sessions exploring the evolving understanding of schizophrenia and bipolar I disorder.

Learn more about our medical events and scientific exchange opportunities: https://t.co/PVo0zx3sF9

#OneBMS